Literature DB >> 10877368

Role of poly-(ADP-ribose) synthetase in lipopolysaccharide-induced vascular failure and acute lung injury in pigs.

M Albertini1, M G Clement, C L Lafortuna, M Caniatti, S Magder, K Abdulmalek, S N Hussain.   

Abstract

PURPOSE: To assess the contribution of poly (adenosine 5'-diphosphate ribose) synthetase (PARS) to the development of bacterial lipopolysaccharide (LPS)-induced acute lung injury and vascular failure in pigs.
MATERIALS AND METHODS: Four groups of anesthetized, paralyzed, and mechanically ventilated domestic white pigs. Group 1 served as control, whereas Escherichia coli LPS (20 microg/kg/h) was continuously infused in group 2. Group 3 received 20 mg/kg injection of 3-aminobenzamide (a selective inhibitor of PARS activity) 15 minutes before LPS infusion. Only 3-aminobenzamide and not LPS was injected in group 4. All animals were examined for 180 minutes. Systemic and pulmonary hemodynamics and lung mechanics were measured during the experimental period. Lung wet/dry ratio, bronchoalveolar lavage (BAL) protein levels and cell counts and lung nitrotyrosine (footprint of peroxynitrite) immunostaining were also measured in a few animals.
RESULTS: LPS infusion evoked a progressive decline in systemic arterial pressure, a small increase in cardiac output, and biphasic elevation of pulmonary arterial pressure. Lung compliance declined progressively, whereas lung and total respiratory resistance rose significantly after LPS infusion. Prominent nitrotyrosine immunostaining was detected around small airways and pulmonary endothelium of LPS-infused animals. No significant changes in lung wet/dry ratio and BAL protein levels and cell counts were produced by LPS infusion. Pretreatment with 3-aminobenzamide did not alter the systemic and pulmonary hemodynamic responses to LPS infusion but eliminated the rise in pulmonary and total respiratory resistance.
CONCLUSIONS: We concluded that PARS activation plays an important role in the changes of lung mechanics associated with LPS-induced acute lung injury but had no role in vascular failure.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10877368     DOI: 10.1053/jcrc.2000.7903

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  7 in total

1.  Endothelial transcytosis of myeloperoxidase confers specificity to vascular ECM proteins as targets of tyrosine nitration.

Authors:  S Baldus; J P Eiserich; A Mani; L Castro; M Figueroa; P Chumley; W Ma; A Tousson; C R White; D C Bullard; M L Brennan; A J Lusis; K P Moore; B A Freeman
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

Review 2.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Mol Aspects Med       Date:  2013-01-29

3.  Quantitative trait analysis of the development of pulmonary tolerance to inhaled zinc oxide in mice.

Authors:  Scott C Wesselkamper; Lung Chi Chen; Terry Gordon
Journal:  Respir Res       Date:  2005-07-18

4.  Effect of HA330 resin-directed hemoadsorption on a porcine acute respiratory distress syndrome model.

Authors:  Xuefeng Xu; Chune Jia; Sa Luo; Yanming Li; Fei Xiao; Huaping Dai; Chen Wang
Journal:  Ann Intensive Care       Date:  2017-08-14       Impact factor: 6.925

5.  Identification of Key Metabolites for Acute Lung Injury in Patients with Sepsis.

Authors:  Pei-Quan Wang; Jing Li; Li-Li Zhang; Hong-Chun Lv; Su-Hua Zhang
Journal:  Iran J Public Health       Date:  2019-01       Impact factor: 1.429

6.  H2 Inhibits the Formation of Neutrophil Extracellular Traps.

Authors:  Kohsuke Shirakawa; Eiji Kobayashi; Genki Ichihara; Hiroki Kitakata; Yoshinori Katsumata; Kazuhisa Sugai; Yoji Hakamata; Motoaki Sano
Journal:  JACC Basic Transl Sci       Date:  2022-01-12

7.  PARP-1 inhibitor, DPQ, attenuates LPS-induced acute lung injury through inhibiting NF-κB-mediated inflammatory response.

Authors:  Gang Wang; Xiaojia Huang; Yongjin Li; Kangkang Guo; Pengbo Ning; Yanming Zhang
Journal:  PLoS One       Date:  2013-11-21       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.